Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease

Blood - Tập 122 - Trang 3778-3783 - 2013
Kelsie M. Bernot1, John S. Nemer1, Ramasamy Santhanam1, Shujun Liu2, Nicholas A. Zorko1, Susan P. Whitman1, Kathryn E. Dickerson1,3, Mengzi Zhang1,4, Xiaojuan Yang1,4, Kathleen K. McConnell1, Elshafa H. Ahmed1, Maura R. Muñoz1, Ronald F. Siebenaler1, Gabriel G. Marcucci1, Bethany L. Mundy-Bosse1, Daniel L. Brook1, Sabrina Garman1, Adrienne M. Dorrance1, Xiaoli Zhang1,5, Jianying Zhang1,5
1The Ohio State University Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH;
2The Hormel Institute, University of Minnesota, Austin, MN
3Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH
4Division of Pharmaceutics, College of Pharmacy
5Center for Biostatistics, The Ohio State University, Columbus, OH

Tóm tắt

Key PointsThe MllPTD/wt:Flt3ITD/wt mouse is a relevant AML model in which the miR-29b–mediated epigenetics-kinome crosstalk is targetable by bortezomib. An original liposomal formulation of bortezomib eradicates AML and yields curative therapy for MllPTD/wt:Flt3ITD/wt AML.

Tài liệu tham khảo